Article
Hypereosinophilic Syndrome Subtype Predicts Responsiveness to Glucocorticoids.
The journal of allergy and clinical immunology. In practice - 1 Jan 2000
Khoury Paneez, Abiodun Annalise O, Holland-Thomas Nicole, Fay Michael P, Klion Amy D
Abstract excerpt
BACKGROUND: Glucocorticoids (GCs) are considered first-line treatment for platelet-derived growth factor α (PDGFRA)-negative hypereosinophilic syndromes (HESs). Despite this, little is known about clinical predictors of GC responsiveness in HES. OBJECTIVE: Knowledge of clinical and laboratory predictors of GC response before initiation of GC could lead to more rational selection of subjects with HES for whom...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.